从临床样本和乳制品中分离出的克菲尔念珠菌的抗真菌药物敏感性谱。

IF 2.6 4区 医学 Q3 INFECTIOUS DISEASES
Zahra Zareshahrabadi, Samin Khaliji, Maryam Roudbari, Kamiar Zomorodian
{"title":"从临床样本和乳制品中分离出的克菲尔念珠菌的抗真菌药物敏感性谱。","authors":"Zahra Zareshahrabadi, Samin Khaliji, Maryam Roudbari, Kamiar Zomorodian","doi":"10.1155/2024/6594366","DOIUrl":null,"url":null,"abstract":"<p><p>Exploring drug susceptibility is a critical endeavor in the scientific community, setting the stage for advancements in understanding and combating various pathogens. <i>Candida kefyr</i> has emerged as a significant pathogen, particularly affecting immunocompromised individuals with hematologic malignancies and HIV/AIDS conditions. This study aimed to assess the antifungal susceptibility profile of <i>Candida kefyr</i> isolates obtained from clinical samples and dairy products. A total of 134 <i>Candida kefyr</i> yeast isolates were retrieved from three distinct groups: (1) healthy individuals (<i>n</i> = 41), (2) patients (<i>n</i> = 24) including hematologic malignancy (<i>n</i> = 9), HIV/AIDS (<i>n</i> = 7), and diabetes (<i>n</i> = 8), (3) dairy products (milk, yogurt, and cheese, <i>n</i> = 69) stored at -70°C in the Shiraz University of Medical Science. All <i>Candida kefyr</i> isolates were previously identified using conventional and molecular methods. Susceptibility to antifungal drugs, including caspofungin, fluconazole, itraconazole, voriconazole, and amphotericin B, was determined using the microdilution method following CLSI-M27-A3 protocols, with results interpreted according to CLSI-M27-S4 guidelines. The study emphasizes the clear variation in antifungal susceptibility testing of <i>Candida kefyr</i> strains when compared across different groups, including patients, healthy people, and dairy products. According to the results, across all groups, a high minimum inhibitory concentration of fluconazole is evident, and healthy individuals show the highest minimum inhibitory concentration geometric means (4.0681). Also, 79.1% of the isolates were wild type to amphotericin B, with the lowest minimum inhibitory concentration compared to other antifungals tested. This suggests that amphotericin B was more effective against <i>Candida kefyr</i>. These findings showed fewer susceptibilities of <i>Candida kefyr</i> to both triazole and echinocandin classes of antifungal agents. Additionally, it is noteworthy that individuals without medical conditions exhibited higher minimum inhibitory concentration rates to these antifungal agents in comparison to those with underlying health conditions. Consequently, timely diagnosis and appropriate therapeutic interventions emerge as imperative in the effective management of candidiasis cases.</p>","PeriodicalId":50715,"journal":{"name":"Canadian Journal of Infectious Diseases & Medical Microbiology","volume":null,"pages":null},"PeriodicalIF":2.6000,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11442036/pdf/","citationCount":"0","resultStr":"{\"title\":\"Antifungal Drug Susceptibility Profile of <i>Candida kefyr</i> Isolated from Clinical Samples and Dairy Products.\",\"authors\":\"Zahra Zareshahrabadi, Samin Khaliji, Maryam Roudbari, Kamiar Zomorodian\",\"doi\":\"10.1155/2024/6594366\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Exploring drug susceptibility is a critical endeavor in the scientific community, setting the stage for advancements in understanding and combating various pathogens. <i>Candida kefyr</i> has emerged as a significant pathogen, particularly affecting immunocompromised individuals with hematologic malignancies and HIV/AIDS conditions. This study aimed to assess the antifungal susceptibility profile of <i>Candida kefyr</i> isolates obtained from clinical samples and dairy products. A total of 134 <i>Candida kefyr</i> yeast isolates were retrieved from three distinct groups: (1) healthy individuals (<i>n</i> = 41), (2) patients (<i>n</i> = 24) including hematologic malignancy (<i>n</i> = 9), HIV/AIDS (<i>n</i> = 7), and diabetes (<i>n</i> = 8), (3) dairy products (milk, yogurt, and cheese, <i>n</i> = 69) stored at -70°C in the Shiraz University of Medical Science. All <i>Candida kefyr</i> isolates were previously identified using conventional and molecular methods. Susceptibility to antifungal drugs, including caspofungin, fluconazole, itraconazole, voriconazole, and amphotericin B, was determined using the microdilution method following CLSI-M27-A3 protocols, with results interpreted according to CLSI-M27-S4 guidelines. The study emphasizes the clear variation in antifungal susceptibility testing of <i>Candida kefyr</i> strains when compared across different groups, including patients, healthy people, and dairy products. According to the results, across all groups, a high minimum inhibitory concentration of fluconazole is evident, and healthy individuals show the highest minimum inhibitory concentration geometric means (4.0681). Also, 79.1% of the isolates were wild type to amphotericin B, with the lowest minimum inhibitory concentration compared to other antifungals tested. This suggests that amphotericin B was more effective against <i>Candida kefyr</i>. These findings showed fewer susceptibilities of <i>Candida kefyr</i> to both triazole and echinocandin classes of antifungal agents. Additionally, it is noteworthy that individuals without medical conditions exhibited higher minimum inhibitory concentration rates to these antifungal agents in comparison to those with underlying health conditions. Consequently, timely diagnosis and appropriate therapeutic interventions emerge as imperative in the effective management of candidiasis cases.</p>\",\"PeriodicalId\":50715,\"journal\":{\"name\":\"Canadian Journal of Infectious Diseases & Medical Microbiology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2024-09-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11442036/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Canadian Journal of Infectious Diseases & Medical Microbiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1155/2024/6594366\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian Journal of Infectious Diseases & Medical Microbiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2024/6594366","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

摘要

探索药物敏感性是科学界的一项重要工作,为了解和抗击各种病原体奠定了基础。克菲尔念珠菌已成为一种重要的病原体,尤其影响血液系统恶性肿瘤和艾滋病毒/艾滋病患者的免疫功能低下。本研究旨在评估从临床样本和乳制品中分离出的克菲尔念珠菌对抗真菌的敏感性。研究人员从设拉子医科大学的三个不同组别中提取了共 134 株克菲尔念珠菌酵母分离物:(1)健康人(n = 41);(2)患者(n = 24),包括血液恶性肿瘤(n = 9)、艾滋病毒/艾滋病(n = 7)和糖尿病(n = 8);(3)储存在 -70°C 的乳制品(牛奶、酸奶和奶酪,n = 69)。所有克菲氏念珠菌分离物均已使用传统方法和分子方法进行过鉴定。对抗真菌药物(包括卡泊芬净、氟康唑、伊曲康唑、伏立康唑和两性霉素 B)的敏感性是按照 CLSI-M27-A3 协议使用微量稀释法测定的,结果按照 CLSI-M27-S4 指南解释。该研究强调,在对不同群体(包括患者、健康人群和乳制品)进行比较时,克菲氏念珠菌菌株的抗真菌药敏试验存在明显差异。结果显示,在所有群体中,氟康唑的最低抑菌浓度明显较高,健康人的最低抑菌浓度几何平均数(4.0681)最高。此外,79.1%的分离菌株对两性霉素 B 呈野生型,与其他测试的抗真菌药物相比,其最低抑菌浓度最低。这表明两性霉素 B 对克菲尔念珠菌更有效。这些研究结果表明,克菲氏念珠菌对三唑类和棘白菌素类抗真菌药物的敏感性较低。此外,值得注意的是,与有潜在健康问题的人相比,没有健康问题的人对这些抗真菌剂的最小抑菌浓度表现出更高的敏感性。因此,及时诊断和适当的治疗干预是有效治疗念珠菌病病例的当务之急。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Antifungal Drug Susceptibility Profile of Candida kefyr Isolated from Clinical Samples and Dairy Products.

Exploring drug susceptibility is a critical endeavor in the scientific community, setting the stage for advancements in understanding and combating various pathogens. Candida kefyr has emerged as a significant pathogen, particularly affecting immunocompromised individuals with hematologic malignancies and HIV/AIDS conditions. This study aimed to assess the antifungal susceptibility profile of Candida kefyr isolates obtained from clinical samples and dairy products. A total of 134 Candida kefyr yeast isolates were retrieved from three distinct groups: (1) healthy individuals (n = 41), (2) patients (n = 24) including hematologic malignancy (n = 9), HIV/AIDS (n = 7), and diabetes (n = 8), (3) dairy products (milk, yogurt, and cheese, n = 69) stored at -70°C in the Shiraz University of Medical Science. All Candida kefyr isolates were previously identified using conventional and molecular methods. Susceptibility to antifungal drugs, including caspofungin, fluconazole, itraconazole, voriconazole, and amphotericin B, was determined using the microdilution method following CLSI-M27-A3 protocols, with results interpreted according to CLSI-M27-S4 guidelines. The study emphasizes the clear variation in antifungal susceptibility testing of Candida kefyr strains when compared across different groups, including patients, healthy people, and dairy products. According to the results, across all groups, a high minimum inhibitory concentration of fluconazole is evident, and healthy individuals show the highest minimum inhibitory concentration geometric means (4.0681). Also, 79.1% of the isolates were wild type to amphotericin B, with the lowest minimum inhibitory concentration compared to other antifungals tested. This suggests that amphotericin B was more effective against Candida kefyr. These findings showed fewer susceptibilities of Candida kefyr to both triazole and echinocandin classes of antifungal agents. Additionally, it is noteworthy that individuals without medical conditions exhibited higher minimum inhibitory concentration rates to these antifungal agents in comparison to those with underlying health conditions. Consequently, timely diagnosis and appropriate therapeutic interventions emerge as imperative in the effective management of candidiasis cases.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.30
自引率
0.00%
发文量
108
审稿时长
>12 weeks
期刊介绍: Canadian Journal of Infectious Diseases and Medical Microbiology is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies related to infectious diseases of bacterial, viral and parasitic origin. The journal welcomes articles describing research on pathogenesis, epidemiology of infection, diagnosis and treatment, antibiotics and resistance, and immunology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信